Barclays
EPRX icon

Barclays’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Barclays’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.4K Buy
+2,136
New +$15.2K ﹤0.01% 4750

Other funds holding EPRX

Beutel, Goodman & Co
Beutel, Goodman & Co Toronto, Ontario, Canada $12.7B AUM 12.76% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Natixis
Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return
TCI Wealth Advisors
TCI Wealth Advisors Tucson, Arizona $2.49B AUM 17.07% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Barclays's EPRX Position: Q3 2026 in Review

Barclays opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q3 2026: 2,136 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #4750 among its holdings.

8 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Barclays held 2,136 shares of Eupraxia Pharmaceuticals worth $19.4K as of Q3 2026.
  • Eupraxia Pharmaceuticals was a new Barclays position in Q3 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4750 holding.
  • 8 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.